Re-processing of biological products: regulatory considerations from the CBER perspective.

Shacter E

Division of Therapeutic Proteins, CBER, FDA, Rockville, Maryland 20852, USA.

Dev Biol (Basel). 2003;113:105-7; discussion 115-6.

Abstract

摘要

相似文献

Dev Biol (Basel). 2003;113:105-7; discussion 115-6.

Dev Biol (Basel). 2003;113:101-4; discussion 115-6.

Dev Biol (Basel). 2003;113:3-120.

Bioanalysis. 2011 Jan;3(1):81-95. doi: 10.4155/bio.10.161.

J Parenter Sci Technol. 1991 Sep-Oct;45(5):218-23.

Dev Biol (Basel). 2003;113:9-14.

Vaccine. 2013 Feb 18;31(9):1264-7. doi: 10.1016/j.vaccine.2012.12.056. Epub 2013 Jan 9.

BioDrugs. 2009;23(4):217-29. doi: 10.2165/11317110-000000000-00000.

AAPS PharmSciTech. 2011 Dec;12(4):1264-75. doi: 10.1208/s12249-011-9684-0. Epub 2011 Sep 27.

Trends Biotechnol. 2013 Aug;31(8):479-92. doi: 10.1016/j.tibtech.2013.05.011. Epub 2013 Jul 10.

Amino Acids. 2022 Apr;54(4):663-673. doi: 10.1007/s00726-021-03087-4. Epub 2021 Oct 17.

20分钟写一篇综述，助力文献阅读效率提升50倍。

大模型驱动的PubMed中文搜索引擎

学术文献翻译模型，支持多种主流文档格式。